HUMA
Humacyte, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Last price
0.65
▼ 0.03 (4.61%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
0.65
Prev close
0.68
Day high
0.70
Day low
0.63
Volume
9.37M
Market cap
$178.40M
P/E (TTM)
—
52W range
0.53 – 2.55
Day trading desk
Gap from prior close
-4.55%
Prior close 0.68
VWAP
—
—
Relative volume
0.00×
Quiet session
Session range
—
0.65 – 0.65
Position in range
—
—
ATR (14D)
0.07
10.79% of price
Prior day high
0.71
PDH
Prior day low
0.66
PDL
Bid / ask spread
—
Quote not published
Session volume
—
Avg 11.26M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+6.12%
+7.5%
1M
+0.47%
-3.3%
3M
-37.06%
-40.2%
6M
-43.19%
-54.3%
YTD
-33.19%
-45.5%
1Y
-60.61%
-80.6%
3Y
-84.68%
-158.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on HUMA open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+6.04K
Net buying
Buy transactions
3
97.82K shares
Sell transactions
2
91.77K shares
Net transactions
+5
Buys less sells
Sell : buy shares
0.9 : 1
Mixed
Insider-held shares
15.57M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 17, 26 | JONES KEITH ANTHONY Director |
BUY | 30.00K | $17.82K | Direct |
| May 19, 26 | SEBELIUS KATHLEEN G Director |
BUY | 56.82K | $50.00K | Direct |
| May 18, 26 | CONSTANTINO MICHAEL T Director |
BUY | 11.00K | $9.84K | Direct |
| May 18, 26 | SANDER DALE A Chief Financial Officer |
SELL | 45.89K | $41.15K | Direct |
| May 18, 26 | PARIKH SHAMIK J Officer |
SELL | 45.89K | $41.15K | Direct |
| Nov 14, 25 | SANDER DALE A Chief Financial Officer |
STOCK | 311.10K | $0 | Direct |
| Nov 14, 25 | PARIKH SHAMIK J Officer |
STOCK | 311.10K | $0 | Direct |
| Aug 20, 25 | DOUGAN BRADY W Director |
SELL | 2.24M | $3.73M | Indirect |
| Aug 20, 25 | NIKLASON LAURA E Chief Executive Officer |
SELL | 2.24M | $3.73M | Indirect |
| Apr 14, 25 | SCHEESSELE WILLIAM JOHN Officer |
BUY | 6.49K | $10.00K | Direct |
| Apr 10, 25 | SANDER DALE A Chief Financial Officer |
BUY | 20.00K | $30.60K | Indirect |
| Apr 10, 25 | PARIKH SHAMIK J Officer |
BUY | 7.50K | $11.63K | Direct |
| Apr 8, 25 | SEBELIUS KATHLEEN G Director |
BUY | 50.00K | $66.00K | Direct |
| Apr 8, 25 | GREEN CHARLES BRUCE Director |
BUY | 6.00K | $7.74K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
CONSTANTINO MICHAEL T |
Director | 43.95K | Purchase |
DOUGAN BRADY W |
Director | — | Sale |
GREEN CHARLES BRUCE |
Director | 8.40K | Purchase |
JONES KEITH ANTHONY |
Director | 30.00K | Purchase |
NIKLASON LAURA E |
Chief Executive Officer | — | Sale |
PARIKH SHAMIK J |
Officer | 272.71K | Sale |
SANDER DALE A |
Chief Financial Officer | 307.81K | Sale |
SCHEESSELE WILLIAM JOHN |
Officer | 22.02K | Purchase |
SEBELIUS KATHLEEN G |
Director | 148.03K | Purchase |
Fundamentals
Market cap$178.40M
Enterprise value$165.38M
Revenue (TTM)$2.12M
Gross profit$-79.37M
EBITDA$-103.23M
Net income$-96.67M
EPS (TTM)$-0.52
Free cash flow$-58.39M
Total cash$79.90M
Total debt$66.88M
Book value / share$0.05
Shares outstanding277.80M
Float251.03M
Short % of float11.75%
Dividend yield—
Beta (5Y)2.47
Valuation & profitability ratios
Trailing P/E—
Forward P/E-2.59
PEG ratio—
Price / sales—
Price / book12.35
EV / revenue77.97
EV / EBITDA-1.60
Gross margin0.00%
Operating margin-6649.26%
Profit margin0.00%
Return on equity-547.87%
Return on assets-49.87%
Debt / equity213.94
Current ratio6.21
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $2.04M | $0 | $0 | $0 | — |
| Operating revenue | $2.04M | $0 | $0 | $0 | — |
| Cost of revenue | $9.70M | $0 | — | — | — |
| Gross profit | -$7.66M | $0 | — | — | — |
| Research & development | $69.30M | $88.60M | $76.55M | $63.26M | -21.8% |
| Selling, general & admin | $31.17M | $25.80M | $23.50M | $22.88M | +20.8% |
| Total operating expense | $100.47M | $114.40M | $100.05M | $84.58M | -12.2% |
| Operating income | -$108.14M | -$114.40M | -$100.05M | -$84.58M | +5.5% |
| Net interest income | -$8.66M | -$5.17M | -$1.13M | -$3.57M | -67.5% |
| Pre-tax income | -$40.83M | -$148.70M | -$110.78M | -$11.96M | +72.5% |
| Net income | -$40.83M | -$148.70M | -$110.78M | -$11.96M | +72.5% |
| Net income to common | -$40.83M | -$148.70M | -$110.78M | -$11.96M | +72.5% |
| Basic EPS | -0.26 | -1.26 | -1.07 | -0.12 | +79.4% |
| Diluted EPS | -0.26 | -1.26 | -1.07 | -0.12 | +79.4% |
| EBIT | -$29.58M | -$139.42M | -$104.18M | -$5.76M | +78.8% |
| EBITDA | -$22.24M | -$132.23M | -$96.46M | $2.44M | +83.2% |
| Basic shares | 158.16M | 118.48M | 103.42M | 103.05M | +33.5% |
| Diluted shares | 158.16M | 118.48M | 103.42M | 103.05M | +33.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $50.50M | $44.94M | $80.45M | $149.77M | — | +12.4% |
| Cash & short-term investments | $50.50M | $44.94M | $80.45M | $151.88M | — | +12.4% |
| Accounts receivable | $441.00K | $0 | $0 | $31.00K | — | — |
| Inventory | $13.59M | $0 | — | — | — | — |
| Total current assets | $67.80M | $47.86M | $83.28M | $154.21M | — | +41.7% |
| Property, plant & equipment | $47.69M | $38.55M | $44.10M | $50.09M | — | +23.7% |
| Total assets | $116.37M | $137.87M | $128.22M | $204.30M | — | -15.6% |
| Total current liabilities | $18.37M | $19.95M | $18.44M | $19.58M | — | -7.9% |
| Current debt | — | — | — | $8.57M | — | — |
| Long-term debt | $35.44M | — | $38.60M | $20.34M | $27.36M | — |
| Total debt | $64.85M | $16.54M | $18.85M | $50.07M | — | +292.1% |
| Total liabilities | $113.26M | $190.54M | $114.68M | $87.37M | — | -40.6% |
| Retained earnings | -$726.85M | -$686.01M | -$537.31M | -$426.54M | — | -6.0% |
| Shareholder equity | $3.11M | -$52.67M | $13.55M | $116.93M | — | +105.9% |
| Working capital | $49.42M | $27.91M | $64.83M | $134.63M | — | +77.1% |
| Net tangible assets | $3.11M | -$52.67M | $13.55M | $116.93M | — | +105.9% |
| Shares issued | 193.00M | 130.03M | 103.67M | 103.23M | — | +48.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$40.83M | -$148.70M | -$110.78M | -$11.96M | +72.5% |
| Depreciation & amortisation | $7.34M | $7.19M | $7.72M | $8.21M | +2.2% |
| Stock-based compensation | $9.75M | $6.14M | $6.83M | $6.18M | +58.9% |
| Change in working capital | -$23.39M | $311.00K | $6.57M | $1.03M | -7,622.5% |
| Operating cash flow | -$105.04M | -$98.12M | -$73.31M | -$71.13M | -7.1% |
| Capital expenditure | -$884.00K | -$1.57M | -$2.28M | -$1.05M | +43.8% |
| Investing cash flow | -$884.00K | -$1.57M | -$173.00K | $4.84M | +43.8% |
| Dividends paid | $0 | $0 | — | — | — |
| Financing cash flow | $61.49M | $114.18M | $4.51M | -$1.45M | -46.2% |
| Free cash flow | -$105.93M | -$99.69M | -$75.58M | -$72.18M | -6.3% |
| End cash position | $50.85M | $95.29M | $80.80M | $149.77M | -46.6% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $495.00K | $467.00K | $753.00K | $301.00K | $517.00K | — | +6.0% |
| Operating revenue | $495.00K | $467.00K | $753.00K | $301.00K | $517.00K | — | +6.0% |
| Cost of revenue | $2.04M | $9.08M | $260.00K | $213.00K | $147.00K | — | -77.6% |
| Gross profit | -$1.54M | -$8.62M | $493.00K | $88.00K | $370.00K | — | +82.1% |
| Research & development | $19.46M | $14.61M | $17.27M | $22.01M | $15.42M | — | +33.3% |
| Selling, general & admin | $7.93M | $7.62M | $7.61M | $7.81M | $8.14M | — | +4.1% |
| Total operating expense | $27.39M | $22.22M | $24.88M | $29.82M | $23.55M | — | +23.3% |
| Operating income | -$28.93M | -$30.84M | -$24.39M | -$29.73M | -$23.18M | — | +6.2% |
| Net interest income | -$1.94M | -$2.59M | -$2.02M | -$1.71M | -$2.34M | — | +25.1% |
| Pre-tax income | -$17.62M | -$24.80M | -$17.51M | -$37.66M | $39.14M | — | +29.0% |
| Net income | -$17.62M | -$24.80M | -$17.51M | -$37.66M | $39.14M | — | +29.0% |
| Net income to common | -$17.62M | -$24.80M | -$17.51M | -$37.66M | $36.77M | — | +29.0% |
| Basic EPS | -0.09 | — | -0.11 | -0.24 | 0.28 | -0.16 | — |
| Diluted EPS | -0.09 | — | -0.11 | -0.24 | 0.28 | -0.16 | — |
| EBIT | -$15.35M | -$21.71M | -$14.90M | -$35.11M | $42.14M | — | +29.3% |
| EBITDA | -$13.56M | -$19.92M | -$13.03M | -$33.25M | $43.97M | — | +31.9% |
| Basic shares | 197.85M | — | 158.31M | 155.44M | 131.50M | 126.98M | — |
| Diluted shares | 197.85M | — | 158.31M | 155.44M | 131.76M | 126.98M | — |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $48.54M | $50.50M | $19.49M | $38.03M | $62.85M | -3.9% |
| Cash & short-term investments | $48.54M | $50.50M | $19.49M | $38.03M | $62.85M | -3.9% |
| Accounts receivable | $434.00K | $441.00K | $1.08M | $394.00K | $488.00K | -1.6% |
| Inventory | $9.92M | $13.59M | $18.42M | $11.07M | $8.02M | -27.0% |
| Total current assets | $63.60M | $67.80M | $41.35M | $51.73M | $73.70M | -6.2% |
| Property, plant & equipment | $46.08M | $47.69M | $49.28M | $35.63M | $37.40M | -3.4% |
| Total assets | $110.56M | $116.37M | $91.51M | $138.79M | $162.55M | -5.0% |
| Total current liabilities | $16.19M | $18.37M | $25.58M | $21.09M | $20.03M | -11.9% |
| Long-term debt | $35.87M | $35.44M | — | — | — | +1.2% |
| Total debt | $65.90M | $64.85M | $29.82M | $15.12M | $15.85M | +1.6% |
| Total liabilities | $98.93M | $113.26M | $96.26M | $134.74M | $126.51M | -12.6% |
| Retained earnings | -$744.47M | -$726.85M | -$702.04M | -$684.53M | -$646.88M | -2.4% |
| Shareholder equity | $11.62M | $3.11M | -$4.75M | $4.05M | $36.04M | +273.9% |
| Working capital | $47.41M | $49.42M | $15.77M | $30.64M | $53.68M | -4.1% |
| Net tangible assets | $11.62M | $3.11M | -$4.75M | $4.05M | $36.04M | +273.9% |
| Shares issued | 222.02M | 193.00M | 158.84M | 156.34M | 155.12M | +15.0% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$17.62M | -$24.80M | -$17.51M | -$37.66M | $39.14M | +29.0% |
| Depreciation & amortisation | $1.79M | $1.79M | $1.86M | $1.86M | $1.83M | +0.1% |
| Stock-based compensation | $3.17M | $2.47M | $2.46M | $2.33M | $2.49M | +28.3% |
| Change in working capital | -$1.30M | -$8.31M | -$4.12M | -$1.40M | -$9.56M | +84.3% |
| Operating cash flow | -$25.10M | -$26.12M | -$23.90M | -$26.41M | -$28.60M | +3.9% |
| Capital expenditure | -$175.00K | -$39.00K | -$49.00K | -$568.00K | -$228.00K | -348.7% |
| Investing cash flow | -$175.00K | -$39.00K | -$49.00K | -$568.00K | -$228.00K | -348.7% |
| Dividends paid | — | $0 | — | — | — | — |
| Financing cash flow | $23.32M | $57.17M | -$44.59M | $2.17M | $46.74M | -59.2% |
| Free cash flow | -$25.28M | -$26.16M | -$23.95M | -$26.98M | -$28.83M | +3.4% |
| End cash position | $48.89M | $50.85M | $19.84M | $88.39M | $113.20M | -3.9% |
Options analytics
Put / call volume
4.30
Put-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
2.50
+289.3% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
+50.0%
Puts bid over calls
Call volume
37
Contracts, this expiry
Put volume
159
Contracts, this expiry
Heaviest call OI
0.50
0 contracts
Heaviest put OI
2.50
15 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.10 | -0.16 | -54.8% |
| Mar 2026 | -0.12 | -0.09 | +21.7% |
| Sep 2025 | -0.16 | -0.11 | +30.5% |
| Dec 2025 | -0.14 | -0.13 | +3.7% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.10 | 3 | $1.11M | +269.7% |
| Next quarter | -0.08 | 4 | $1.84M | +294.7% |
| Current year | -0.40 | 4 | $3.51M | +72.3% |
| Next year | -0.25 | 4 | $21.73M | +518.8% |
Analyst targets & ownership
Mean target$1.85
High target$4.00
Low target$1.00
Implied upside184.62%
Analyst count5
ConsensusBUY
Strong buy / Buy1 / 3
Hold1
Sell / Strong sell0 / 0
Held by insiders5.61%
Held by institutions26.61%
Institutions holding194
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
0.65
+0.37% from price
SMA 20
0.66
-3.38% from price
SMA 50
0.73
-11.46% from price
SMA 100
0.83
-21.72% from price
SMA 200
0.97
-34.00% from price
EMA 12
0.65
-0.65% from price
EMA 26
0.68
-4.27% from price
EMA 50
0.74
-12.00% from price
RSI (14)
46.7
Neutral
MACD (12,26,9)
-0.02
Hist 0.01
ATR (14)
0.07
10.93% of price
Realised vol 30D
112.7%
Annualised
Bollinger upper
0.78
20, 2σ
Bollinger lower
0.55
20, 2σ
50 / 200 cross
Death
0.73 vs 0.97
Trend bias
Below 200
-34.00%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
3.15
More volatile than market
Correlation to SPY
0.35
Loosely linked
Realised vol 30D
112.7%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-77.8%
Peak to trough
Max drawdown 5Y
-96.8%
Peak to trough
ATR 14
0.07
10.93% of price
Beta (reported)
2.47
5Y monthly, from filing
Short interest
Shares short
31.49M
Prior 31.60M
Change vs prior
-0.3%
Shorts covering
% of float
11.75%
Elevated
% of shares out
11.68%
Against total outstanding
Days to cover
4.3
Liquid
Float
251.03M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 13, 26 | Benchmark | MAINTAINED | Speculative Buy | Speculative Buy |
| Jul 28, 26 | BTIG | MAINTAINED | Buy | Buy |
| Jun 17, 26 | TD Cowen | MAINTAINED | Buy | Buy |
| Jun 16, 26 | BTIG | MAINTAINED | Buy | Buy |
| Jun 11, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jun 8, 26 | BTIG | MAINTAINED | Buy | Buy |
| Jun 1, 26 | Benchmark | MAINTAINED | Speculative Buy | Speculative Buy |
| May 26, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 14, 26 | TD Cowen | MAINTAINED | Buy | Buy |
| May 13, 26 | BTIG | MAINTAINED | Buy | Buy |
| Apr 28, 26 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Apr 28, 26 | BTIG | MAINTAINED | Buy | Buy |
SEC filings
Periodic Financial Reports
10-Q · 2026-08-12
Corporate Changes & Voting Matters
8-K · 2026-07-31
Corporate Changes & Voting Matters
8-K · 2026-06-11
Corporate Changes & Voting Matters
8-K · 2026-06-10
Corporate Changes & Voting Matters
8-K · 2026-06-09
Corporate Changes & Voting Matters
8-K · 2026-06-05
Offering Registrations
S-8 · 2026-05-14
Periodic Financial Reports
10-Q · 2026-05-13
Headlines
Humacyte (HUMA) Q2 2026 Earnings Call Transcript
Motley Fool · 5d ago
Humacyte Announces Lancet Digital Health Publication of V007 Phase 3 Hemodialysis Access Trial Results
GlobeNewswire · 5d ago
Board-Certified Vascular and Endovascular Surgeon Performs First Commercial Symvess® Implantation; Cites Bioengineered Blood Vessel as “Revolutionary Advancement”
GlobeNewswire · 6d ago
Humacyte (HUMA) Faces A Fresh Test As Its $4 Fair Value Narrative Holds
Simply Wall St. · 10d ago
Humacyte (HUMA) Stock Looks Stretched On Book Value Yet Reasonable After A 93% Fall
Simply Wall St. · 11d ago
Humacyte (HUMA) Reports Stronger Phase 3 Dialysis Results In Women
Simply Wall St. · 11d ago
Humacyte Inc (HUMA) (Q2 2026) Earnings Call Highlights: Strong Trial Results and Strategic ...
GuruFocus.com · 11d ago
Humacyte, Inc. Q2 2026 Earnings Call Summary
Moby · 11d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.